Bourse
Stock filings

MPLT insider trades & Congress trades

MapLight Therapeutics, Inc.: public insider filings and Congress disclosures, in one place.

6insider buys + sells
0Congress trades
0 / 6insider buys / sells, 90 days
–latest buying cluster

Bourse has recorded 6 open-market insider transactions in MapLight Therapeutics, Inc. (MPLT) (0 purchases with code P and 6 sales with code S), the most recent on October 15, 2026.

In the last 90 days: 0 purchases by 0 insiders ($0) and 6 sales by 6 ($1.06M).

Insider transactions

SEC Form 4, open-market purchases (P) and sales (S) only. Awards, option exercises and tax withholding are excluded. “After” shows the stock’s return over the month following the trade, where available.

DateInsiderRoleTypeSharesPriceValueAfter 1M
Oct 15, 2026Kreitzer AnatolChief Discovery OfficerSell12,248$7.84$96K–
Oct 15, 2026Gillis JonathanCAO and Interim CFOSell10,167$8.08$82K–
Oct 15, 2026Lillie James WoodruffChief Scientific OfficerSell11,513$8.08$93K–
Oct 15, 2026Hanson KristopherGeneral CounselSell9,020$8.08$73K–
Oct 15, 2026Foff Erin PennockChief Medical OfficerSell15,355$8.08$124K–
Oct 15, 2026Kroeger Christopher A.Chief Executive OfficerSell73,691$8.08$595K–

Data as of October 22, 2026. Public filings only. A purchase or sale by a politician or an insider does not by itself imply any wrongdoing.

New to these filings? Read how to read a Form 4, how Congress trades are disclosed and what insider cluster buying means. Sources and limits are on the Methodology page.

See these filings as they land

Bourse collects Congress trades, SEC Form 4 insider filings and 13F fund holdings in one live feed, and flags insider buying clusters automatically. Free to start.

Bourse provides financial data and editorial information, parts of which are generated by AI. This page is for general education only. It is not personalised investment advice or a recommendation to buy or sell any financial instrument. Make your own decisions.